Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B
| Autor: | Pattama Kusuman, Kunsuda Cheirsilpa, Jantarika Tawpa, Charinthip Pothijaroen, Kamonwan Soonklang, Kesinee Yingcharoen, Chirayu U. Auewarakul, Pitchayachuda Chunnuan, Thanachote Kamalapirat, Jiraporn Dechma, Teerapat Ungtrakul |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Carcinoma Hepatocellular Subgroup analysis Risk prediction models Antiviral Agents 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Chronic hepatitis Risk Factors Virology Internal medicine Asian country Humans Medicine 030212 general & internal medicine Framingham Risk Score Hepatology Receiver operating characteristic business.industry Liver Neoplasms Thailand medicine.disease digestive system diseases Infectious Diseases Hepatocellular carcinoma Cohort 030211 gastroenterology & hepatology business |
| Zdroj: | Journal of Viral Hepatitis. 28:1034-1041 |
| ISSN: | 1365-2893 1352-0504 |
| DOI: | 10.1111/jvh.13517 |
| Popis: | Chronic hepatitis B (CHB) infection-associated hepatocellular carcinoma (HCC) is a major health problem in Asian countries. Several HCC risk prediction models have been developed using either treated or untreated CHB patients. However, there is limited validation of these risk scores in a treated and untreated mixed CHB patient cohort. This study analysed and validated HCC risk scores among 2208 CHB patients who enrolled in the HCC surveillance programme in Thailand during July 2010. The baseline clinical and radiologic data of these CHB patients were applied to calculate various HCC risk scores. There were 20 patients (0.9%) with HCC development at the 5.9-year follow-up. The areas under the receiver operating characteristic curves (AUROCs) predicting HCC risk at 5 years were 0.80 (0.68-0.91), 0.73 (0.60-0.85), 0.79 (0.67-0.91), 0.70 (0.58-0.82), 0.72 (0.59-0.85), 0.76 (0.63-0.87) and 0.77 (0.64-0.89) for the GAG-HCC, CU-HCC, REACH-B, PAGE-B, mPAGE-B, CAMD and AASL scores, respectively. The overall HCC risk scores were accurate and comparable. However, the subgroup analysis revealed better HCC-risk-predictive performance in the treated patients, while performance was less helpful in those not fulfilling criteria for antiviral therapy. Clinicians should be aware of these data when using the HCC risk score in untreated CHB patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|